Letter to the Editor: Enhancing the rigor and impact of cholangiocarcinoma research: Addressing key concerns in the PTPN9-FGFR2 interaction study

Hepatology. 2024 Sep 1;80(3):E44-E45. doi: 10.1097/HEP.0000000000000932. Epub 2024 Jun 24.

Authors

Meng Zhu^{1

2}, Mengqi Qu^{1

2}, Shengxia Lv^{1

2}, Jinfang Zhang^{1

2}, Yongsheng Zhang^{1

2}, Fuzhen Pan^{1

2}

Affiliations

¹ Cancer Center, Shenzhen Hospital (Futian) of Guangzhou University of Chinese Medicine, Shenzhen, Guangdong, China.
² School of Basic Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang Province, China.

No abstract available

Publication types

Letter

MeSH terms

Bile Duct Neoplasms*
Cholangiocarcinoma*
Humans
Receptor, Fibroblast Growth Factor, Type 2* / genetics

Substances

Receptor, Fibroblast Growth Factor, Type 2
FGFR2 protein, human